Article: Nicotinamide Riboside and Metabolic Cofactors Improve Gut Health in Fatty Liver Disease: Preclinical Findings

PrevNext
Digestive/Gut Health Liver Disease Liver Health Preclinical

Nicotinamide Riboside and Metabolic Cofactors Improve Gut Health in Fatty Liver Disease: Preclinical Findings

Synopsis

The gut barrier controls what passes into the body and protects organs like the liver. An unhealthy diet and lifestyle cause gut microbiome imbalances (dysbiosis) and gut barrier damage, which worsen non-alcoholic fatty liver disease (NAFLD). This study tested a combination of metabolic cofactors (betaine, N-acetylcysteine, L-carnitine, nicotinamide riboside) in mice with diet-induced NAFLD. Treatment improved gut structure, reduced gut leakiness, lowered inflammation, and increased gut cell growth. It also changed gut bacteria composition and beneficial short-chain fatty acids. These effects helped slow NAFLD progression by improving gut-liver communication.

Journal

International Journal of Molecular Sciences

Share

Read more

Cancer

Tracking Nicotinamide Riboside Uptake in Cancer Cells: Preclinical Findings

Synopsis Researchers developed a bioluminescent probe (BiNR) to visualize how nicotinamide riboside (NR)—a vitamin B3–derived NAD+ booster—is taken up by cells and tissues in real time. This tool ...

Read more
Preclinical

Porcine Placental Extract Increases NAD+ and Energy in Human Skin Cells: Preclinical Findings

Synopsis Nicotinamide adenine dinucleotide (NAD+) is an important molecule that helps our cells produce energy. As we age, NAD+ levels naturally decrease in many tissues, which can contribute to a...

Read more